Question special
Lead Moderator

The FDA recently approved the combination therapy of nivolumab and ipilimuab (a CTLA-4 inhibitor) for treatment of unresectable metastatic melanoma based on the results of the CheckMate 069 study. Any thoughts about utilizing this combination therapy of nivolumab and ipilimuab for advanced/metastatic RCC?